Compare Cassava Sciences Inc (FLNA) vs Centrus Energy Corp (LEU) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Centrus Energy (LEU) trades at $147.14, down 4.38% on the day, amid neutral technical signals and mixed earnings performance. The stock shows elevated valuation ratios with a P/E of 75.18 and P/S of 6.68, while profitability metrics include a 10.23% net income margin and 8.05% ROE. Recent news highlights Centrus' strategic positioning as a key supplier of High-Assay Low-Enriched Uranium (HALEU) for advanced nuclear reactors, supported by new multi-year supply contracts with Antares and Radiant announced in September 2026.

The investment case balances strong growth potential in the nuclear fuel market against execution risks and high valuation. Analyst consensus suggests 46% buy ratings with a $218.10 price target, implying significant upside, but investors face risks from cash flow volatility, competitive pressures, and the company's reliance on successful capacity expansion. The recent $500 million stock offering provides capital for growth but may dilute existing shareholders.